Co-Diagnostics, Inc. Annual Report - How They Did This Year

I’m writing this guide to help you understand how Co-Diagnostics, Inc. (CODX) performed this year. My goal is to translate complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Co-Diagnostics is a molecular diagnostics company based in Salt Lake City. They create tests that detect diseases like COVID-19, flu, and tuberculosis by analyzing DNA and RNA. Their "secret sauce" is a technology called "Co-Primers." They claim this makes their tests more accurate and cheaper to produce because they avoid paying royalties to other patent holders. The company makes money by selling diagnostic kits and equipment, alongside its CoSara Diagnostics joint venture in India.

2. The Big Pivot: From Labs to Home Testing

The company is in a major transition. They previously sold tests to clinical labs. Now, they are betting their future on the "Co-Dx PCR platform." This is a portable, 2-pound device that connects to a smartphone to provide lab-quality results in about 30 minutes.

They shifted resources toward a "multiplex" test that detects Flu A/B, COVID-19, and RSV simultaneously. They believe this "all-in-one" test is more attractive to the market. Clinical trials began in November 2024, and the company is working toward FDA clearance to sell this platform for home and clinical use.

3. Financial Health: The "Cash-Burning" Phase

Co-Diagnostics is in a high-risk, startup-like phase. For the year ending December 31, 2023, the company reported $6.5 million in revenue. They are not yet profitable, reporting a loss of $23.6 million for the same period. They fund their research by selling stock and using grant money.

• The Funding: They held approximately $54.8 million in cash and investments. They also received $1.2 million from the NIH and $7.8 million in grants from the Bill & Melinda Gates Foundation to develop TB and HPV tests.
• The Risk: Because they aren't self-sustaining, they may sell more stock later. This causes "dilution," where the company issues more shares, reducing your ownership percentage of the business. You should monitor how quickly they spend their cash to ensure they can reach their goals without needing to raise more money.

4. Key Risks to Watch

• Regulatory Hurdles: The company’s future depends on FDA approval for their home-testing platform. If the FDA denies approval or demands more expensive trials, the path to profit becomes longer and costlier.
• Competition: They are a small player in a large market. They compete against giants like Abbott, Roche, and Danaher, which have much larger budgets and established sales networks.
• Global Dependence: Much of their business relies on their joint venture in India (CoSara). This exposes them to local price controls and regulations. Additionally, changes in the value of the Indian Rupee against the U.S. Dollar can impact their reported earnings.

5. The Bottom Line

Co-Diagnostics is a "bet on the future." They have interesting technology and a clear goal to enter the home-testing market, but they are currently spending more than they earn. They act like a biotech startup: high potential, but high risk.

This is not a stable, dividend-paying company. If you want a speculative play on the future of at-home testing, watch their FDA progress and their "burn rate" in quarterly filings. This will show how long their $54.8 million cash pile will last.